MedTrace Logo

Mesenchymal Stem Cells Treatment for AIDS Patients at Late Stage

NCT05939167 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2025-08-12

No results posted yet for this study

Summary

The goal of this study is to conduct a prospective, double-blind, randomized placebo-controlled clinical trial to investigate the safety and efficacy of mesenchymal stem cells treatment for AIDS patients at late stage.

Conditions

  • AIDS

Interventions

DRUG

mesenchymal stem cell

Mesenchymal stem cell dose is 0.75-1.0×10\*6/kg and is transplanted by intravenous infusion. For the mesenchymal stem cell standard treatment group, the cells are used for three times(at week 0, 2,4 after recruitment) and the mesenchymal stem cell enhanced treatment group, the cells are used for six times(at week 0, 2,4,24,26,28 after recruitment).

OTHER

saline

saline is used as placebo in the placebo comparator group

Sponsors & Collaborators

  • Beijing 302 Hospital

    collaborator OTHER

  • Shenzhen Third People's Hospital

    collaborator OTHER

  • Fifth Hospital of Shijiazhuang City

    collaborator OTHER

  • Beijing YouAn Hospital

    collaborator OTHER

  • Cell Energy Life Sciences Group Co. LTD

    lead INDUSTRY

Principal Investigators

  • Fu-Sheng Wang, Doctor · Beijing 302 Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-10
Primary Completion
2027-07-10
Completion
2028-07-10

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05939167 on ClinicalTrials.gov